Word on the Street
"This is clinical development so there are going to be some setbacks."
– Gil Van Bokkelen, CEO of Athersys Inc. and chairman of the Alliance for Regenerative Medicine
"You can see a slight change in subject one's pulse here. But I can tell you, his pulse was substantially lower than my own pulse when this vector was going in."
– Amit Nathwani, investigator on a trial testing Factor IX gene therapy for hemophilia B, describing monitoring patients for adverse reaction during infusions
"If programs stumble, jobs are at stake."
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter